Slideshow

New FDA Warning

Author(s):

James Phelps, MD

A rare but serious reaction to this treatment can have immunological consequences. As with all medications, however, the latest alert does not change how psychiatrists manage the risks.

Related Videos
lithium
McIntyre
emergency
World Bipolar Day
bipolar
bipolar
bipolar
journey
Related Content
bipolar
May 13th 2025

Diagnosis in Bipolar Disorder: Dealing With Comorbidity

David N. Osser, MD
Blue Light, Depression, and Bipolar Disorder
August 4th 2021

Blue Light, Depression, and Bipolar Disorder

Chris Aiken, MD Kellie Newsome, PMH-NP
pills
April 30th 2025

April in Review: Updates on the Psychiatric Treatment Pipeline

Leah Kuntz
Four Myths About Lamotrigine
August 3rd 2021

Four Myths About Lamotrigine

Chris Aiken, MD Kellie Newsome, PMH-NP
bipolar disorder
April 7th 2025

Online Survey Reveals Clinicians’ Top Concerns in BDI, Schizophrenia Treatment

Grace Koennecke
FDA
April 1st 2025

New NDA Submitted: Bysanti to Treat Acute Bipolar I and Schizophrenia

Leah Kuntz
© 2025 MJH Life Sciences

All rights reserved.